These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 12941196)

  • 21. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register.
    Thorstenson A; Bergman M; Scherman-Plogell AH; Hosseinnia S; Ljungberg B; Adolfsson J; Lundstam S
    Scand J Urol; 2014 Jun; 48(3):231-8. PubMed ID: 24666102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
    Aizer AA; Urun Y; McKay RR; Kibel AS; Nguyen PL; Choueiri TK
    BJU Int; 2014 May; 113(5b):E67-74. PubMed ID: 24053727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.
    Bölükbas S; Kudelin N; Eberlein M; Fisseler-Eckhoff A; Schirren J
    Thorac Cardiovasc Surg; 2012 Sep; 60(6):390-7. PubMed ID: 22207364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
    Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
    Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?
    Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T
    Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival.
    Beisland C; Medby PC; Beisland HO
    Scand J Urol Nephrol; 2004; 38(4):299-305. PubMed ID: 15669589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.
    Gershman B; Moreira DM; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
    Eur Urol; 2017 Aug; 72(2):300-306. PubMed ID: 28094055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What is the impact of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma?].
    Oya M; Murai M
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1732-7. PubMed ID: 12402422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes.
    Parekh DJ; Cookson MS; Chapman W; Harrell F; Wells N; Chang SS; Smith JA
    J Urol; 2005 Jun; 173(6):1897-902. PubMed ID: 15879771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance following radical or partial nephrectomy for renal cell carcinoma.
    Lam JS; Leppert JT; Figlin RA; Belldegrun AS
    Curr Urol Rep; 2005 Feb; 6(1):7-18. PubMed ID: 15610692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lymphatic metastases in renal cell carcinoma. What is the value of operation and adjuvant therapy?].
    Mickisch GH
    Urologe A; 1999 Jul; 38(4):326-31. PubMed ID: 10444789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunotherapy in the management of metastatic renal carcinoma].
    Fischetti G; Cuzari S; Leone P; De Martino P; Musy M; Mariani S; Fraioli A; Valentini MA
    Minerva Urol Nefrol; 2002 Jun; 54(2):113-7. PubMed ID: 12070458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
    De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
    Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node dissection in renal cell carcinoma.
    Capitanio U; Becker F; Blute ML; Mulders P; Patard JJ; Russo P; Studer UE; Van Poppel H
    Eur Urol; 2011 Dec; 60(6):1212-20. PubMed ID: 21940096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?].
    Gilbert N; Merseburger AS; Kramer MW
    Urologe A; 2017 May; 56(5):604-609. PubMed ID: 28314973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma.
    Zini L; Capitanio U; Perrotte P; Jeldres C; Shariat SF; Arjane P; Widmer H; Montorsi F; Patard JJ; Karakiewicz PI
    Urology; 2009 Feb; 73(2):342-6. PubMed ID: 19041122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.